Open AccessMesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy
Author(s) -
Dahbour Said,
Jamali Fatima,
Alhattab Dana,
AlRadaideh Ali,
Ababneh Osama,
AlRyalat Nosaiba,
AlBdour Muawyeh,
Hourani Bayan,
Msallam Mohammed,
Rasheed Murad,
Huneiti Ammar,
Bahou Yacoub,
Tarawneh Emad,
Awidi Abdalla
Publication year - 2017
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.12759
Subject(s) - medicine , multiple sclerosis , expanded disability status scale , mesenchymal stem cell , lesion , adverse effect , clinical trial , radiological weapon , surgery , oncology , pathology , immunology
Summary Aims This open‐label prospective phase I/ II a clinical study used autologous bone marrow‐derived mesenchymal stromal cells ( BM ‐ MSC s) followed by mesenchymal stromal cells conditioned media ( MSC ‐ CM ) for the first time to treat multiple sclerosis ( MS ) patients. The primary goal was to assess the safety and feasibility and the secondary was efficacy. The correlation between the MSC ‐ CM content and treatment outcome was investigated. Methods Ten MS patients who failed conventional therapy were enrolled. Adverse events were recorded to assess safety. The Expanded Disability Status Scale ( EDSS ) was the primary efficacy measurement, the secondary included clinical (25 WFT , 9‐ PHT ), cognitive ( MMS ), ophthalmology ( OCT , VEP ), and radiological ( MRI lesion and volume) tests. The MSC s‐ CM concentration of 27 inflammatory biomarkers was investigated. Results The treatment protocol was well tolerated by patients. There was an overall trend of improvement in all the tests, except the lesion volume which increased significantly. A decrease of 4 and 3.5 points on the EDSS was achieved in two patients. We report a correlation between a decreased lesion number at baseline and higher IL ‐6, IL ‐8, and VEGF MSC ‐ CM content. Conclusion The used protocol was safe and feasible with possible efficacy. The addition of MSC ‐ CM could be related to the magnitude of EDSS improvement observed.